by certify that this correspondence is being deposited with the US Postal Service with sufficient postage as Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. Date: August 27, 2003 PATENT Docket No. GC723 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE In re Application of Bott et al. Group Art Unit: 1645 Examiner: Unassigned Serial No.: 10/092,227 Filed: March 5, 2002 For: High Throughput Mutagenesis Screening Method Information Disclosure Statement Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56. This Information Disclosure Statement: (a) accompanies the new patent application submitted herewith. 37 CFR §1.97(a). (b) is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application

(c)

☐ as far as is known to the undersigned, is filed before the mailing date of a

(d) is filed after the first Office Action and more than three months after the application filing date or PCT national stage date of entry filing but, as far

as is known to the undersigned, prior to the mailing date of either a final

as set forth in 37 CFR §1.491.

first Office Action on the merits.

	rejection or a notice of allowance, whichever occurs first, and is accompanied be either the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Authorization to charge Deposit Account No. 07-1048 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement is provided in the Transmittal Letter submitted herewith in duplicate.								
	allowar Transr No. 07 as spe consid	(e) is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by authorization (in the Transmittal Letter submitted herewith in duplicate) to charge Deposit Account No. 07-1048 the fee (\$180.00) set forth in 37 CFR §1.17(I)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Supplemental Information Disclosure Statement.							
[If either of b	oxes (c	l) or (e) is checked above, the following "certification" under 37 CFR							
§1.97(e) may need to be completed.] The undersigned certifies that:									
	Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.								
	No item of information contained in this Information Disclosure Stateme was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.								
A copy of the	items o	n Form PTO-1449 is supplied: PCT International Search Report for							
PCT/	,	filed with attached patents and publications.							
☐ ead	ch ⊠n	one only those listed below:							
A concise exp	lanation	n of relevance of the items listed on PTO-1449 is:							
	\boxtimes	not given							
		given for each listed item							
		given for only non-English language listed item(s)							
	in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.								

Serial No. 10/092,227

Page 3

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: August 27, 2003

Registration No. 33,228

Genencor International, Inc. 925 Page Mill Road Palo Alto, CA 94304-1013

Tel: 650 846-4072 Fax: 650 845-6504

	- 1			JULIAL SILIALIU.			7 trans				
Attorney Docket No.: GC723 Serial No.: 10/092,227											
Applicant: Bott, et al.											
Filing Date: March 5, 2002 to AUt 2 2000 u				Group: 1645							
Page1 of1				Date of this Submission: September 2, 2003							
US PATENT DOCUMENTS											
Examiner's	Document					Sub-	Filing				
Initial	Number	Date	Name		Class	Class	Date				
	6,171,820 B1	01/09/01	Short	,							
	5,827,719	10/27/98	Sandal et al.								
	6,251,604 B1	06/26/01	Lietz								
	5,798,208	08/25/98	Crea								
	5,556,747	09/17/96	Kumar								
FOREIGN PATENT DOCUMENTS											
Examiner's	Document					Sub-	Translation				
Initials	Number	Date	Country		Class	Class	Yes/No				
<i>y</i>	WO 91/16427	1/16427 10/31/91 PCT			RECEIVED SEP 9 3 2003						
<u> </u>	WO 94/14963	07/07/94	PCT		INCC	EIVE					
A	WO 94/14964	07/07/94	PCT		SEP	0.0	J				
4	WO 00/05389	02/03/00	PCT	<i>T</i> E	CH CELIER	3 2003					
	OTHER DOCUMENTS WO 00/05389 02/03/00 PCT PCH CENTER 1600/2900										
Examiner's	1999/2900										
Initials	Author, Title, Date, Pertinent Pages, etc.										
J	Airaksinen, Antero et al., « Modified base compositions at degenerate positions of a mutagenic oligonucleotide enhance randomness in site-saturation mutagenesis, » Nucleic Acids Research, 26(2):576-581, 1998.										
J	Juffer, A. H. et al., « Adsorption of Proteins onto Charged Surfaces: A Monte Carlo Approach with Explicit Ions, » J. of Computational Chemistry, 17:1783-1803, 1996.										
	Kolattukudy, P.E., « Cutinases from fungi and pollen,» Ed. B. Borgstrom and H.L. Brockman, <u>Lipases</u> , Elsevier, pp 471-504, 1984.										
J	Longhi, Sonia et al., « Atomic Resolution (1.0 Å) Crystal Structure of Fusarium solani Cutinase: Stereochemical Analysis, » J. of Molecular Biology, 268(4): 779-799, 1997.										
J	Longhi, Sonia et al., « Dynamics of <i>Fusarium solani</i> Cutinase Investigated Through Structural Comparison Among Different Crystal Forms of Its Variants, » Proteins: Structure, Function and Genetics, 26:442-458, 1996.										
V	Martinez, Chrislaine et al., « Engineering cysteine mutants to obtain crystallographic phases with a cutinase from Fusarium solani pisi, » Protein Engineering, 6 :157-165, 1993.										
	Van Gemeren, I.A. et al., «Expression and Secretion of Defined Cutinase Variants by Aspergillus awamori,» Appl. Environm. Microbiology, 64:2794-2799, 1998.										
	<u> </u>										
						· · · · · · · · · · · · · · · · · · ·					
Formities Park County and											
Examiner				Date Considered							
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not											
considered. Include copy of this form with next communication to applicant.											
considered. Include copy of this form with next communication to applicant.											